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Abstract. Alzheimer's disease (AD) is the main 
neurodegenerative disorder, causing total intellectual disability in 
patients suffering from it. It is considered an important public 
health problem of the 21st century due to its high global 
prevalence and socioeconomic impact. The amyloid hypothesis of 
AD proposes that β-amyloid peptide plays a key role in this 
disease. Several pharmacological strategies have been developed  
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with the aim of inhibiting the formation of β-amyloid peptides, such as β-secretase 
and γ-secretase inhibitors. Other anti-amyloid treatments include passive and active 
immunotherapies focused on inhibiting β-amyloid peptide aggregation. However, the 
most recent phase 3 clinical trials of solanezumab, a humanized monoclonal antibody 
that promotes the clearance of β-amyloid in the brain, show no efficacy of this 
antibody in patients with mild AD, suggesting that the amyloid hypothesis of AD 
should be revised. In this manuscript, the current and ongoing treatments acting 
primarily on the β-amyloid protein are reviewed. 
 
Introduction 
 
 Alzheimer's disease (AD) is the most frequent progressive 
neurodegenerative disorder that causes dementia among the world's 
population over 65 years (between 50 and 70% of the cases of dementia) [1]. 
The disease is chronic and progressive, causing deficits of multiple brain 
functions (mainly at the cortex and hippocampus levels) including memory, 
thinking, orientation, comprehension, calculation, learning ability and 
language [2].  
 Despite the great scientific and clinical advances in AD in the last 30 
years, the treatments currently available are only symptomatic; thus meaning 
that they alleviate the symptoms of the disease by acting at different levels of 
the neuropathological process [2]. Although they improve the life quality of 
the patients, none can actually cure or delay the rapid and fatal progression 
of the disease. 
 Nowadays, there are only four drugs on the market approved for the 
treatment of AD. These drugs can be divided in two groups: 
acetylcholinesterase inhibitors (AChEI) and N-methyl-D-aspartic acid 
receptor (NMDAR) antagonists. AChEI includes donepezil, rivastigmine and 
galantamine [2, 4]. The mechanism of action of AChEI is to increase 
cholinergic transmission by inhibiting acetylcholinesterase in the synaptic 
cleft and therefore they may slightly increase the cognitive ability of patients 
with AD. Since in AD the levels of the neurotransmitter glutamate are 
pathologically elevated, memantine (MEM) is an NMDAR receptor 
antagonist that reduces excitotoxicity by blocking this ionotropic receptor. 
Both groups of drugs are indicated for the treatment of patients with 
moderate or severe AD [3,4]. However, it has been shown that none of these 
drugs actually represents a cure for the disease, since its effects are only 
palliative and its efficacy decrease with time. 
 Notwithstanding, new treatments and therapeutic strategies are being 
investigated in order to delay the course of the disease. These are mainly 
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directed to the neuropathological complexity of AD, encompassing multiple 
targets and are intended to be administered in the early stages of AD. 
 For future treatments to be effective, it will be necessary to develop new 
diagnostic techniques that allow an earlier diagnosis of AD in a pre-clinical 
phase (before symptoms appear), or even to predict the development of the 
disease. 
 The prevention of AD is a realistic challenge for researchers, but to 
make it possible it is necessary a better understanding of the aetiology and 
the extent to which environmental factors and lifestyle influence the risk of 
developing the disease. 
 
1. Alzheimer’s disease: Hypotheses 
 
 The cause or causes that promote the development of AD are still 
unknown. However, different hypotheses (Fig. 1) have been proposed thus 
contributing to understand the complex neurodegenerative process of this 
disease [5-8]. Most experts agree that it develops as a result of a 
combination of multiple modifiable and non-modifiable risk factors (age, 
sex, family history and genetics, environmental and lifestyle) rather than a 
single cause [9-11]. 
 The two proposed etiological hypotheses most accepted by the 
scientific community currently are: 
 
1. The hypothesis of the amyloid cascade, which suggests that the 
neurodegenerative process observed in the brains of patients with 
AD would be mainly due to the cytotoxic events triggered by the 
formation, aggregation and deposition of β-amyloid peptides 
[6,9]. This hypothesis has been strongly supported by researchers 
because of the genetic findings in molecular biology studies, 
opening new lines in the search for drugs for the treatment of AD, 
such as inhibitors of β and γ-secretase or enhancers of α-secretase 
[4]. According to this hypothesis, the initiation of AD would be 
triggered by the following process: APP (amyloid precursor 
protein) would be metabolized by the amyloidogenic route, which 
would cause an excess in the production of the β-amyloid peptide 
(βA) and / or a defect of its elimination [4,5]. 
2. Tau phosphorylation hypothesis. βA protein is obtained from the 
catabolism of APP, a membrane protein with a single domain (an 
intracellular and extracellular part) found in different cell types, 
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including neurons, glial cells, astrocytes and oligodendrocytes, 
[7,8]. It is encoded by a gene located on chromosome 21 which, 
when expressed, gives rise to 8 isoforms, with APP695 being the 
most abundant in the brain. This protein is cleaved by α-, β-, and 
γ-secretase enzymes and a complex of proteins containing the 
presenilin gene (PSEN1). In a physiological situation, following 
the non-amyloidogenic pathway, APP is catabolized by                        
α-secretase, producing an APPα fragment (s) which remains in the 
extracellular space, and an 83-amino acid carboxy-terminal 
fragment (C83). APPα regulates neuronal excitability, improves 
synaptic plasticity, learning, memory and increases the resistance 
of neurons to oxidative and metabolic stress [5-8]. However, in a 
neuropathological situation, APP is metabolized by the 
amyloidogenic pathway, in which BACE1 (β-secretase 1) cleaves 
APP by the N-terminal end and the γ-secretase cleaves the             
C-terminal end, obtaining the fragments Aβ40 / 42, which remain 
in the extracellular space, and a C-terminal fragment of 99 amino 
acids (C99), which can be transported into the cell and 
translocated to the nucleus, where it could induce expression of 
genes that promote neuronal death by apoptosis [6,7]. APP 
regulates neuronal survival, protection against toxic external 
stimuli, neurite outgrowth, synaptic plasticity and cell adhesion. 
Notwithstanding, when it is transformed into βA 40/42 peptides, it 
interferes with synapses, decreases neuronal plasticity, alters the 
energy metabolism and glucose, induces oxidative stress and 
mitochondrial dysfunction, and disrupts cellular calcium 
homeostasis [7]. Differential cleavage by β-secretase produces 
different βA peptides: βA40 is the predominant species, whereas 
βA42 is the major component of senile plaques. The peptide βA42 
is more prone to aggregation and more neurotoxic than βA40. 
According to this, it has been proposed that βA is the pathogenic 
species in AD. In this way, βA42 is oligomerized and 
accumulated as senile plaques in the brain, thus exerting toxic 
effects on neuronal synapses. In a second stage, there would be a 
glial response, activation of the astrocytes and the surrounding 
microglia, which would release cytokines or components of the 
complement system leading to inflammatory responses. Likewise, 
oxidative stress is established in the neuron and there is an 
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alteration in calcium ion homeostasis, which causes 
hyperactivation of protein kinases and the inactivation of 
phosphatases. For this reason, the tau protein is 
hyperphosphorylated and forms the neurofibrillary tangles, which 
accumulate in the synapses and in the neuronal bodies causing 
neuronal death by apoptosis and a deficiency of neurotransmitters. 
All this cascade of processes ends in instituting dementia [7]. 
 
          
 
Figure 1. Alzheimer’s disease hallmarks and its process. 
 
 Thus, both βA (mainly βA42) and tau proteins have been the main 
targets for modifying therapies of AD [4]. From this point of view, AD 
could be prevented or treated effectively by the decrease in the production 
of βA42 and the phosphorylation of the tau protein, in addition to the 
prevention of the aggregation or poor folding of these proteins, thus 
neutralizing or eliminating the toxic aggregated or poorly folded forms of 
these proteins, or a combination of these modalities [4-9]. 
 Likewise, alternative hypotheses such as the alteration of 
mitochondrial activity, the neuroinflammatory hypothesis, the metabolic 
hypothesis (namely cholesterol and insulin), and the dendritic hypothesis 
have been also proposed [10-15]. All these lines of thought confirm the 
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complexity of this disease, in addition to the fact that the mechanism of 
neuronal death by apoptosis is not yet known at all. 
 
2. Therapeutic strategies for the development of drugs to modify 
the course of Alzheimer's disease 
 
 Given the expected increase in the number of cases of AD patients in the 
coming decades, it is necessary to develop more effective treatments capable 
of modifying the course of the disease. 
 During the last decade, from 1998 to 2011, about 100 compounds 
have been evaluated with the objective of modifying the course of AD. 
Unfortunately, they have failed in the clinical development phase [1,3]. 
The reason for this failure could be explained, as already mentioned, by 
the multifactorial aetiology and pathophysiological complexity of the 
disease. Finding a suitable and effective drug in the whole population 
tested is a very complicated task. 
 Although some key aspects of the pathogenesis of AD remain to be 
solved, the scientific advances of the last 25 years have allowed to 
reasonably establishing several strategies for the development of 
treatments with potential to modify the course of this disease. Thus, 
among the different therapeutic strategies that are being investigated, 
those aimed at reducing the formation of βA42 and the phosphoryla tion 
of the tau protein are the most important [3]. These two types of injuries 
are the ones that have provided the greatest advances in the field, and 
could be the key to the treatment of AD in the near future. 
 Following the amyloid hypothesis of AD, huge efforts have been 
made with the aim of developing effective drugs in the treatment of AD 
[4, 6]. However, the multiple clinical failures of the compounds in 
development have led researchers to question this hypothesis. 
Notwithstanding, new compounds are being investigated, along with new 
diagnostic tools for AD. This is important, since the reason for these 
failures could be the lack of suitable biomarkers that would allow 
recruitment of patients in clinical trials before they reach a very 
advanced phase of the disease, in which any therapeutic intervention is 
useless [1]. 
 The different anti-amyloid strategies are designed to act at different 
points in the metabolism of APP such as decreasing production of βA 
peptides. In the attempt to decrease the production of βA, the current 
research has focused on the modulation of the enzymatic pathways 
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responsible for the abnormal processing of APP, i.e. inhibition of γ                     
and / or β-secretase and α-secretase activation.  
 
2.1. Inhibitors of β-secretase (BACE1) 
 
 The enzyme β-secretase is responsible for initiating the amyloidogenic 
processing pathway of APP [7]. The development of inhibitors of this 
enzyme is quite challenging because, in addition to APP, β-secretase has 
many more substrates, among which we find neuregulin-1, involved in the 
myelination of the peripheral nerves [16-18]. This fact makes the                
non-specific inhibition of the enzyme susceptible of causing adverse 
effects [16]. The structure of the enzyme is another main problem. Since it 
belongs to the class of aspartyl proteases, the inhibitor must be a large 
hydrophilic molecule, which makes it difficult to cross the blood-brain 
barrier [19]. Currently, several compounds are being investigated to 
overcome these obstacles and to make some of them effective in the 
treatment of AD [19]. Recent studies indicate that two inhibitors of                    
β-secretase, E2609 and MK-8931, are extremely effective in reducing the 
production of βA levels up to 80-90% in cerebrospinal fluid (CSF) in 
humans [17-19]. 
 
2.2. Inhibitors and modulators of γ-secretase 
 
 The γ-secretase enzyme is responsible for the final phase of APP 
processing by the amyloidogenic pathway, resulting in βA40 and βA42 
peptides. Although its inhibition was a promising advance for the 
modification of the disease back in 2001, showing for the first time an                 
in vivo decrease in the production of βA, the development of γ-secretase 
inhibitors shows similar problems to those of β-secretase inhibitors                                   
[19-21]. 
 In addition to APP, γ-secretase processes multiple proteins, including 
the Notch protein, responsible for regulating cell proliferation, 
development, differentiation, communication, and cellular survival status 
[20,21]. For this reason, nonspecific inhibition of the enzyme results in 
serious adverse effects, leading to severe limitations in clinical trials. 
 Semagacestat (LY450139) is an example of this therapeutic group. As 
a functional γ-secretase inhibitor, it was shown to decrease βA levels in 
blood and cerebrospinal fluid in humans [22]. However, the results of this 
and other similar studies (NCT00762411; NCT01035138; NCT00762411) 
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showed that semagacestat did not decrease the slow progression of the 
disease and, in addition, its administration was associated with worsening 
cognition. Another example is avagacestat (NCT00810147; 
NCT00890890; NCT00810147; NCT01079819), whose pharmacokinetics 
and effectiveness have been evaluated in several clinical trials in AD 
patients [23-25]. 
 To avoid the adverse effects derived from these γ-secretase inhibitors, 
the use of γ-secretase selective modulators (MSGS), which block the 
enzyme by altering the processing of APP without interfering with the 
signalling of other ways such as Notch, has been proposed [21]. The 
development of MSGS began with the observation that several                      
anti-inflammatory drugs (NSAIDs) decreased βA42 peptide levels in 
human H4 neuroglioma cells as well as transgenic mice [26,27]. Examples 
of these drugs are ibuprofen, sulindac, indomethacin, and flurbiprofen.                      
(R)-Flurbiprofen (tarenflurbil) inhibits cyclooxigenase-1 to a low extent, 
and it was tested in a clinical phase III study for the treatment of AD. 
However, both tarenflurbil and ibuprofen failed in their respective clinical 
trials [27,28]. 
 CHF5074 is a non-steroidal anti-inflammatory derivative devoid of 
cyclooxygenase inhibitory activity [29]. In vitro, CHF5074 behaves as a        
β-secretase modulator, preferentially by inhibiting the production of βA42 
[30,31]. As we have already mentioned, the long-term use of NSAIDs 
confers some protection against AD, which led to the widespread study of 
NSAIDs against the production of βA42. However, negative results 
observed in NSAID clinical trials suggest that protection against AD is not 
a general benefit provided by all these drugs. 
 An example of these MSGS is NIC5-15, a molecule of natural origin. 
Specifically, NIC5-15 is pinitol, a natural cyclic sugar alcohol [32]. 
Interestingly, pinitol also acts as an insulin sensitizer. This compound 
modulates β-secretase and reduces the production of βA without affecting 
the cleavage of the Notch-β-secretase substrate [32,33]. It has been 
suggested that the compound improves function deficit and memory in 
preclinical models of AD neuropathology [33]. Studies in animals and 
human trials have shown that NIC5-15 is safe and also acts as a sensitizer 
for insulin actions [32]. In preclinical studies, at doses higher than those 
previously studied in clinical trials, NIC5-15 was found to interfere with 
βA accumulation. This data suggest that NIC5-15 may be a suitable 
therapeutic agent for the treatment of AD mainly for three reasons: it is a 
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secretory inhibitor preserving Notch and, in addition, it is potentially                         
an insulin sensitizer and is being investigated as an inhibitor of                                
the inflammatory process particularly inhibiting the activation of 
microglia. 
 
2.3. Activation of α-secretase 
 
 Activation of the α-secretase enzyme leads to the processing of APP 
by the non-amyloidogenic pathway, thereby decreasing the amount of APP 
available for the amyloidogenic pathway. The result is the formation of a 
soluble βA, which has been shown to play a neuroprotective and 
synaptogenic stimulatory role. 
 Thus, the activation of α-secretase is an attractive strategy for the 
development of disease modifying drugs. Different compounds related 
with the non-amyloidogenic pathway have been investigated, such as 
agonists of muscarinic acetylcholine receptors, glutamatergic receptors, 
serotoninergic receptors, and activators of protein kinase C (PKC). 
However, not many compounds have been found that effectively modulate 
this pathway in animal models, so not many of these compounds can be 
found in clinical trials. 
 Epigallocatechin gallate (EGCG) is a polyphenolic flavonoid extracted 
from green tea leaves and it is considered its key bioactive ingredient. It 
has been reported to have beneficial clinical effects ranging from                  
anti-tumour, anti-inflammatory and neuroprotective action, and it may also 
have a beneficial effect on cognitive function [34]. It has been proposed 
that EGCG inhibits the formation of toxic βA oligomers, in addition to 
activating α-secretase. A clinical trial (NCT00951834) is currently being 
conducted to evaluate the efficacy of EGCG in early stages of AD. 
 Briostatin 1 is a modulator of PKC which also seems to have 
immunomodulatory effects. There is preclinical data showing that this 
compound increases cognitive ability [35]. 
 Etazolate (EHT0202) stimulates the neurotrophic action of                       
α-secretase and also inhibits neuronal death induced by βA, thus providing 
symptomatic relief and further modifying disease progression. In a recent 
phase IIa clinical study in 159 patients with mild to moderate AD, 
EHT0202 has been shown to be safe and generally well tolerated [36]. 
These early encouraging results further support the development of 
EHT0202 to assess its clinical efficacy and confirm its tolerability in a 
large cohort of patients with AD in a longer period of time [36]. 
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Moreover, acitretin is a retinoid that acts as a retinoic acid receptor 
agonist. It is primarily used to treat severe psoriasis [37]. In preclinical 
models, it increases the expression of ADAM-10, an α-secretase of the 
human amyloid precursor protein (APP) [37-39]. Acitretin has been 
reported to activate the non-amyloidogenic pathway of APP in 
neuroblastoma cells and to reduce βA levels in APP / PS1 transgenic mice. 
[37-39]. 
 
2.4. Amyloid antiaggregants 
 
 The extensive evidence on the neurotoxic and synaptotoxic activity of 
amyloid aggregates, constitute the scientific basis for the development of 
inhibitors of the aggregation of βA peptides. 
 The only inhibitor of βA aggregation to reach phase III is the 3-amino 
acid synthetic 1-propanesulfonic acid (3APS, Alzhemed, tramiprosate) 
[40,41]. This drug was designed to interfere with or antagonize the 
interaction of βA with endogenous glycosaminoglycans. 
Glycosaminoglycans have been shown to promote βA aggregation by 
interfering with the formation of amyloid fibrils and by stabilizing plaque 
deposition [41]. However, the disappointing results of the phase III trial in 
2007 led to the suspension of the European Phase III trial. 
 Colostrinin, a proline-rich polypeptide complex derived from ovine 
colostrum, inhibits βA aggregation and its neurotoxicity in cellular assays, 
and improves cognitive performance in preclinical animal models [42]. 
Although a Phase II trial showed slight improvements in the Mini Mental 
State assessment in patients with mild AD over a 15-month treatment period, 
this beneficial effect was not maintained for another 15 months of additional 
continuous treatment. 
 The compound called scyllo-inositol is capable of stabilizing the 
oligomeric aggregates of βA and inhibiting βA toxicity in the mouse 
hippocampus. An 18-month clinical trial in the search for dose, safety and 
efficacy of scyllo-inositol (ELND005) in mild to moderate AD patients was 
carried out. Three doses of ELND005 (250, 1000, and 2000 mg) were 
evaluated, being 250 mg the most adequate. Future long-term clinical studies 
should be performed to elucidate if there is enough evidence to support or 
rule out an ELND005 benefit in AD. 
 Several compounds with an antiaggregating effect, such as PBT1 
(clioquinol) and PBT2, have been evaluated. Clioquinol was investigated as 
a treatment for AD since it blocks the interaction between metals and βA in 
the brain [45]. It has been proposed that increased levels of bioactive metals 
Therapeutics in Alzheimer's disease 125 
in aging brain accelerate the formation of amyloid plaques, as well as 
neurotoxic oxidative processes. The fundamental reason for the evaluation of 
clioquinol was that it would prevent accumulation of βA and, in addition, 
restore homeostasis of cellular levels of ions such as copper and zinc. 
Unfortunately, these compounds failed during clinical trial phases II and III 
due to lack of efficacy. 
 
2.5. Compounds favouring the elimination of amyloid aggregates 
and deposits 
 
 Another amyloid-directed strategy is based on promoting the clearance 
of aggregates and amyloid deposits. To achieve this, three different 
strategies have been evaluated: 
 
1)   Activation of enzymes responsible for degrading amyloid plaques 
 Amyloid aggregates and plaques are degraded by different 
proteases, including neprilysin, insulin degrading enzyme (IDE), 
plasmin, endothelin-converting enzyme, angiotensin-converting 
enzyme, and metalloproteinases [9,46,47]. In AD, the levels of these 
enzymes decrease, thus contributing to the formation and accumulation 
of amyloid plaques [46]. Despite being an attractive anti-amyloid 
strategy for the development of disease-modifying drugs, no protease 
activator has been evaluated so far due to the lack of specificity of 
these compounds. 
2)   Modulation of βA transport from the brain to the peripheral circulation 
 The transport of βA between the central nervous system (CNS) and 
the peripheral circulation is regulated by; 1) apolipoproteins, with 
APOEε4 promoting the passage of βA from the blood to the brain; 2) 
low density lipoprotein receptor (LRP)-related protein, which increases 
the outflow of βA from the brain into the blood and; 3) the receptor for 
advanced glycation end products (RAGE), which facilitates βA entry 
into the CNS [48-51]. 
   Although different strategies -like peripheral LRP administration- 
have been proposed to increase βA transport from the brain to the 
peripheral circulation, only compounds aimed at inhibiting / 
modulating RAGE have reached clinical development. These include 
PF-0449470052, which failed in the Phase II clinical trial, and 
TTP4000, currently in Phase I clinical trials (NCT01548430). The 
study ended in February 2013, and no results have been published so 
far. 
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 3)  Specific anti-amyloid immunotherapy 
 
 This is the most studied strategy with the aim of reducing amyloid 
burden in AD.  There are two types of anti-amyloid immunotherapy: 
 
a) Active immunotherapy: Active immunization (vaccination) with either 
βA42 (the predominant form of βA in the amyloid plaques of AD) or other 
synthetic fragments has been successfully evaluated in transgenic AD 
mouse models. The assays are generally based on the stimulation of                  
T-cells, B-cells, and the immune response by activating the phagocytic 
capacity of the microglia. The results of the initially promising trials have 
been partially suspended due to the appearance of meningoencephalitis in 
some patients. When the first vaccine (AN1792, consisting of 42 amino 
acid peptide) was tested on patients, it was found to give rise to 
neurological inflammatory processes, such as aseptic meningoencephalitis, 
as a result of an anti-AN1792 autoimmune response. These adverse effects 
forced the discontinuation of Phase II clinical trials [53]. 
 In order to avoid the non-specific immune response derived from 
immunization with complete βA (Aβ42) peptides, a second generation of 
vaccines has been designed by using shorter segments of βA (Aβ1-6) 
peptide, which favored a humoral response to a cellular immune response. 
CAD 106, designed by Novartis, was the first second generation vaccine 
that reached the clinical stages of development [54]. It has recently 
completed Phase II clinical trials, where a specific response of βA 
antibodies was observed in 75% of the patients tested, without giving rise 
to inflammatory adverse responses. ACC-001 has recently completed some 
Phase II trials (NCT01284387 and NCT00479557). Although there is 
another Phase II trial in process (NCT01227564), the pharmaceutical 
company has declined to continue the investigation. There are currently 
other vaccines in preclinical stages of development, such as the peptide 
ACI-24, βA1-15 tetra-palmitoylate reconstituted in a liposome, MER5101 
and AF205 [55-57]. 
 
b) Passive immunization: It consists of passive -intravenous- 
administration of monoclonal or polyclonal antibodies directed against βA 
in the patient. Thus, an anti-βA immune response is achieved without the 
need for a pro-inflammatory reaction mediated by T cells [57]. Transgenic 
animal studies have demonstrated that passive immunization, in addition to 
reducing neuronal amyloid burden, improves cognitive deficits even before 
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the elimination of neuronal amyloid plaques [58]. This could be attributed 
to the neutralization of soluble amyloid oligomers, which are increasingly 
believed to play a fundamental role in the pathophysiological cascade of 
AD [57,58]. 
 Bapineuzumab and solanezumab, the two monoclonal antibodies that 
have reached the most advanced stages of clinical development, failed in 
2012 in two phase III clinical trials as they did not show the expected 
benefits in patients with mild-moderate AD. Bapineuzumab is a humanized 
monoclonal antibody against the N-terminal end of βA (Aβ1-5), while 
solanezumab is a humanized monoclonal antibody designed to bind to the 
central portion of βA (Aβ12-28) [59,60]. It is noteworthy that, despite the 
reduction of key AD biomarkers, such as amyloid brain plaques and 
phosphorylated tau protein in the cerebrospinal fluid, bapineuzumab failed 
to produce significant cognitive improvements in two clinical trials 
[61,62]. 
 New phase III clinical trials with solanezumab are currently underway 
(NCT01127633 and NCT01900665), assessing its efficacy and safety in 
patients with mild AD (NCT02051608), with prodromal AD 
(NCT01224106), and in elderly asymptomatic population at high risk of 
losing memory (NCT02008357) [62]. Another monoclonal antibody, 
gantenerumab, is being tested with the aim of evaluating its modifying 
potential in people at risk of developing AD due to an autosomal dominant  
mutation of the DIAN-TI gene (NCT01760005) [63,64]. Gantenerumab is 
a fully human IgG1 antibody designed to bind with high affinity to a 
conformational epitope on βA fibers [63,64]. The therapeutic basis for this 
antibody is that it acts by degrading the amyloid plaques by a process of 
recruitment of the microglia and activation of phagocytosis. Experimental 
studies in transgenic mice support this hypothesis [65]. In parallel, a 
number of phase III clinical trials evaluating gantenerumab are being 
performed. 
 Specifically, in a phase III clinical trial, infusions of 400 mg of 
solanezumab or placebo once a month for 80 weeks were administered to 
patients with mild to moderate AD. The results seem to indicate a tendency 
to improve cognition with solanezumab in people with mild AD, but it 
does not appear to be statistically significant. Thus, we should be cautious 
and wait for more results. 
 Crenezumab (MABT5102A), is another humanized monoclonal 
antibody in phases of clinical development [66]. In April 2014, a phase II 
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clinical trial was completed to evaluate its efficacy and safety in patients 
with mild-moderate AD (NCT01343966), although the results are not yet 
available. Currently, two phase II trials with crenezumab are underway. 
The most recent began in 2013 in order to evaluate their efficacy and 
safety in asymptomatic patients with the autosomal dominant PSEN1 
mutation (NCT01998841). 
 Other monoclonal antibodies against βA developed so far include            
PF-04360365 (ponezumab), which targets the free C-terminal of βA 
(specifically βA34-41); MABT5102A, which binds to monomers, 
oligomers, βA and fibrils with equally high affinity; and GSK933776A, 
which, similarly to bapineuzumab, targets the N-terminal sequence of βA 
[66]. In addition, other passive immunotherapies, such as those assessing 
GSK933776A, NI-101, SAR-228810 and BAN-2401 are being developed, 
most of which are in Phase I clinical trials.  
 Finally, gammagard™ is an antibody preparation from human plasma. 
Concerning this preparation, a safety record for human use has been 
established for certain autoimmune conditions. Gammagard ™ has also 
been evaluated for the treatment of AD in a small number of patients 
(NCT00818662). These intravenous immunoglobulin mixtures contain a 
small fraction of polyclonal antibodies directed against the βA peptide, 
which is believed to counterbalance the synaptic toxicity caused by βA 
[67-69]. In addition, this intravenous IgG immunoglobulin has 
immunomodulatory effects, besides favoring the phagocytosis of the 
microglia [69]. 
 
3. Conclusion 
 
 Several attempts have been made to treat AD by reducing cerebral βA 
levels. Overall results obtained so far suggest that anti-amyloid drugs, as a 
specific group, could have a detrimental effect on the symptoms of the 
disease. On the other hand, the investigators argued in favor of carefully 
differentiating between these therapeutic approaches according to the 
underlying mechanism, rather than grouping them all together as                
anti-amyloid treatments. In addition, alternative approaches have been 
proposed to explain the failure of the amyloid hypothesis. Specifically, the 
adaptive response hypothesis proposes that βA may accumulate by an 
adaptive response to chronic stress stimuli in the brain [9]. According to 
this, stress stimuli are the pathogenic triggering signals/pathways of the 
late onset of AD and, therefore, would be suitable candidates for 
Therapeutics in Alzheimer's disease 129 
therapeutic intervention in the disease. Such stimuli would include 
oxidative stress, metabolic dysregulation (cholesterol homeostasis, insulin 
resistance, etc.), genetic factors, and inflammatory response. Each of these 
stimuli is capable of eliciting a response in which more βA would be 
generated, and the nature of this response would determine the clinical 
progression of AD. Following this line of thought, acting on these stress 
stimuli could be an adequate pharmacological treatment to curb AD. 
Accordingly, intranasal insulin is recently being evaluated as a promising 
strategy for the treatment of AD. Positive results could confirm that βA is 
not the only noxious agent responsible for AD. 
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